| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Adriamycin-induced interference with cardiac mitochondrial calcium homeostasis
|
Wallace, Kendall B.
|
|
|
7 |
2 |
p. 101-107
|
artikel
|
| 2 |
Adriamycin-induced interference with cardiac mitochondrial calcium homeostasis
|
Wallace, Kendall B.
|
|
2007
|
7 |
2 |
p. 101-107
|
artikel
|
| 3 |
An introduction to the metabolic determinants of anthracycline cardiotoxicity
|
Menna, Pierantonio
|
|
|
7 |
2 |
p. 80-85
|
artikel
|
| 4 |
An introduction to the metabolic determinants of anthracycline cardiotoxicity
|
Menna, Pierantonio
|
|
2007
|
7 |
2 |
p. 80-85
|
artikel
|
| 5 |
Anthracycline cardiotoxicity in breast cancer patients: synergism with trastuzumab and taxanes
|
Gianni, Luca
|
|
|
7 |
2 |
p. 67-71
|
artikel
|
| 6 |
Anthracycline cardiotoxicity in breast cancer patients: synergism with trastuzumab and taxanes
|
Gianni, Luca
|
|
2007
|
7 |
2 |
p. 67-71
|
artikel
|
| 7 |
Anthracycline cardiotoxicity in long-term survivors of childhood cancer
|
Scully, Rebecca E.
|
|
|
7 |
2 |
p. 122-128
|
artikel
|
| 8 |
Anthracycline cardiotoxicity in long-term survivors of childhood cancer
|
Scully, Rebecca E.
|
|
2007
|
7 |
2 |
p. 122-128
|
artikel
|
| 9 |
Anthracycline-induced phospholipase A2 inhibition
|
Swift, Luther
|
|
|
7 |
2 |
p. 86-91
|
artikel
|
| 10 |
Anthracycline-induced phospholipase A2 inhibition
|
Swift, Luther
|
|
2007
|
7 |
2 |
p. 86-91
|
artikel
|
| 11 |
Antioxidant defense against anthracycline cardiotoxicity by metallothionein
|
Kang, Y. James
|
|
|
7 |
2 |
p. 95-100
|
artikel
|
| 12 |
Antioxidant defense against anthracycline cardiotoxicity by metallothionein
|
Kang, Y. James
|
|
2007
|
7 |
2 |
p. 95-100
|
artikel
|
| 13 |
Cardiac safety of liposomal anthracyclines
|
Batist, Gerald
|
|
|
7 |
2 |
p. 72-74
|
artikel
|
| 14 |
Cardiac safety of liposomal anthracyclines
|
Batist, Gerald
|
|
2007
|
7 |
2 |
p. 72-74
|
artikel
|
| 15 |
Dexrazoxane: how it works in cardiac and tumor cells. Is it a prodrug or is it a drug?
|
Hasinoff, Brian B.
|
|
|
7 |
2 |
p. 140-144
|
artikel
|
| 16 |
Dexrazoxane: how it works in cardiac and tumor cells. Is it a prodrug or is it a drug?
|
Hasinoff, Brian B.
|
|
2007
|
7 |
2 |
p. 140-144
|
artikel
|
| 17 |
Genotyping the risk of anthracycline-induced cardiotoxicity
|
Deng, Shiwei
|
|
|
7 |
2 |
p. 129-134
|
artikel
|
| 18 |
Genotyping the risk of anthracycline-induced cardiotoxicity
|
Deng, Shiwei
|
|
2007
|
7 |
2 |
p. 129-134
|
artikel
|
| 19 |
Iron signaling and oxidant damage
|
Kalyanaraman, Balaraman
|
|
|
7 |
2 |
p. 92-94
|
artikel
|
| 20 |
Iron signaling and oxidant damage
|
Kalyanaraman, Balaraman
|
|
2007
|
7 |
2 |
p. 92-94
|
artikel
|
| 21 |
Long-term and short-term models for studying anthracycline cardiotoxicity and protectors
|
Robert, Jacques
|
|
|
7 |
2 |
p. 135-139
|
artikel
|
| 22 |
Long-term and short-term models for studying anthracycline cardiotoxicity and protectors
|
Robert, Jacques
|
|
2007
|
7 |
2 |
p. 135-139
|
artikel
|
| 23 |
Molecular and cellular mechanisms of anthracycline cardiotoxicity
|
Chen, Billy
|
|
|
7 |
2 |
p. 114-121
|
artikel
|
| 24 |
Molecular and cellular mechanisms of anthracycline cardiotoxicity
|
Chen, Billy
|
|
2007
|
7 |
2 |
p. 114-121
|
artikel
|
| 25 |
New iron chelators in anthracycline-induced cardiotoxicity
|
Kaiserová, Helena
|
|
|
7 |
2 |
p. 145-150
|
artikel
|
| 26 |
New iron chelators in anthracycline-induced cardiotoxicity
|
Kaiserová, Helena
|
|
2007
|
7 |
2 |
p. 145-150
|
artikel
|
| 27 |
Novel antioxidants in anthracycline cardiotoxicity
|
Hideg, Kálmán
|
|
|
7 |
2 |
p. 160-164
|
artikel
|
| 28 |
Novel antioxidants in anthracycline cardiotoxicity
|
Hideg, Kálmán
|
|
2007
|
7 |
2 |
p. 160-164
|
artikel
|
| 29 |
Ongoing phase I and II studies of novel anthracyclines
|
Sessa, Cristiana
|
|
|
7 |
2 |
p. 75-79
|
artikel
|
| 30 |
Ongoing phase I and II studies of novel anthracyclines
|
Sessa, Cristiana
|
|
2007
|
7 |
2 |
p. 75-79
|
artikel
|
| 31 |
Other uses of dexrazoxane: savene, the first proven antidote against anthracycline extravasation injuries
|
Langer, Seppo W.
|
|
|
7 |
2 |
p. 151-153
|
artikel
|
| 32 |
Other uses of dexrazoxane: savene, the first proven antidote against anthracycline extravasation injuries
|
Langer, Seppo W.
|
|
2007
|
7 |
2 |
p. 151-153
|
artikel
|
| 33 |
Pathophysiology and diagnosis of cancer drug induced cardiomyopathy
|
Zuppinger, Christian
|
|
|
7 |
2 |
p. 61-66
|
artikel
|
| 34 |
Pathophysiology and diagnosis of cancer drug induced cardiomyopathy
|
Zuppinger, Christian
|
|
2007
|
7 |
2 |
p. 61-66
|
artikel
|
| 35 |
Protection by flavonoids against anthracycline cardiotoxicity: from chemistry to clinical trials
|
Bast, Aalt
|
|
2007
|
7 |
2 |
p. 154-159
|
artikel
|
| 36 |
Role of anthracyclines in the era of targeted therapy
|
Cortés-Funes, Hernán
|
|
|
7 |
2 |
p. 56-60
|
artikel
|
| 37 |
Role of anthracyclines in the era of targeted therapy
|
Cortés-Funes, Hernán
|
|
2007
|
7 |
2 |
p. 56-60
|
artikel
|
| 38 |
Role of mtDNA lesions in anthracycline cardiotoxicity
|
Lebrecht, Dirk
|
|
|
7 |
2 |
p. 108-113
|
artikel
|
| 39 |
Role of mtDNA lesions in anthracycline cardiotoxicity
|
Lebrecht, Dirk
|
|
2007
|
7 |
2 |
p. 108-113
|
artikel
|
| 40 |
The anthracyclines: When good things go bad
|
Minotti, Giorgio
|
|
|
7 |
2 |
p. 53-55
|
artikel
|
| 41 |
The anthracyclines: When good things go bad
|
Minotti, Giorgio
|
|
2007
|
7 |
2 |
p. 53-55
|
artikel
|
Tijdschrift beschrijving